New Phase 3 trial: A Lot-to-Lot Consistency Clinical Trial of PCV13 — Sinovac Biotech Co., Ltd
Why now
Thesis: Sinovac PCV13 lot-consistency trial registration
Catalyst to watch: Trial completion or regulatory submission
Main risk: No efficacy or financial data
Why it matters
Sinovac PCV13 lot-consistency trial registration; no efficacy or financial data.
Details
Sponsor: Sinovac Biotech Co., Ltd; Status: Not Yet Recruiting; Conditions: Pneumococcal Infectious Diseases; Interventions: Sinovac PCV13 lot 1, Sinovac PCV13 lot 2, Sinovac PCV13 lot 3; Enrollment: 1125 (estimated); First posted: 2026-09-22; NCT: NCT07832500
Related assets & topics
HealthcareSources
- clinicaltrials · 2026-09-22 12:00 UTC